<DOC>
	<DOCNO>NCT00003455</DOCNO>
	<brief_summary>RATIONALE : Antineoplastons naturally-occurring substance may also make laboratory . Antineoplastons may inhibit growth cancer cell . PURPOSE : This phase II trial study well antineoplaston therapy work treat woman stage IV breast cancer respond standard therapy .</brief_summary>
	<brief_title>Antineoplaston Therapy Treating Women With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity antineoplastons A10 AS2-1 capsule patient advance breast cancer determine proportion woman experience objective tumor response . - Evaluate adverse effect tolerance regimen patient . OUTLINE : This open-label study . Patients receive oral antineoplaston A10 antineoplaston AS2-1 6 7 time per day . Treatment continue least 6 week . Patients achieve complete partial response may continue therapy disease progression toxic effect occur . Patients follow survival . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV breast cancer unlikely respond exist therapy curative therapy exist Failed prior standard therapy Measurable disease MRI CT scan Tumor must least 2 cm lymph node head , neck , axillary , inguinal , femoral area least 0.5 cm location Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal Status : Not specify Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC least 2,000/mm^3 Platelet count least 50,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL SGOT/SGPT great 5 time upper limit normal No hepatic failure Renal : Creatinine great 2.5 mg/dL No renal failure Cardiovascular : No chronic heart failure No uncontrolled hypertension Pulmonary : No severe lung disease Other : Not pregnant nursing Fertile patient must use effective contraception 4 week study participation No serious medical psychiatric disorder No active infection No serious concurrent disease No serious malabsorption syndrome PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior immunotherapy At least 4 week since prior immunotherapy , except patient disease progression initial therapy Chemotherapy : Recovered prior chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) , except patient disease progression initial therapy Endocrine therapy : Recovered prior hormonal therapy At least 12 week since prior hormonal therapy , except patient disease progression initial therapy Concurrent corticosteroids peritumoral edema allow Radiotherapy : At least 8 week since prior radiotherapy recover Patients multiple tumor receive radiotherapy , , tumor may admit earlier 8 week Surgery : Recovered prior surgery No prior extensive stomach intestinal surgery Other : Prior cytodifferentiating agent allow No prior antineoplaston therapy No concurrent therapy metastatic breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>